Loading…
Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study
Highlights • Co-utilization of TLR5 agonist and nano- vaccine increase it immunogenicity. • Nano-Vac/FliC Increased cellular and Th1 immune responses. • Nano-Vac/FliC shows good immunogenicity in lower dose of immunization.
Saved in:
Published in: | Immunology letters 2017-07, Vol.187, p.19-26 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Highlights • Co-utilization of TLR5 agonist and nano- vaccine increase it immunogenicity. • Nano-Vac/FliC Increased cellular and Th1 immune responses. • Nano-Vac/FliC shows good immunogenicity in lower dose of immunization. |
---|---|
ISSN: | 0165-2478 1879-0542 |
DOI: | 10.1016/j.imlet.2017.05.002 |